Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering
SAN FRANCISCO, April 21, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative...
Read moreDetails